The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Biomarkers, 2002Metabolomic Profiling to Develop Biomarkers for Parkinson's Disease
Metabolomics is the comprehensive study of the repertoire of small molecules present in cells and tissues. The identities, concentrations, and fluxes of these molecules are a final product of...
-
Biomarkers, 2002Assessing the Role of a-Synuclein, a Biomarker for Parkinson's Disease
Alpha-synuclein was first implicated in familial Parkinson's disease but is also a major component of the Lewy body pathology, found in sporadic disease. Over-expression of the gene in fruit flies is...
-
Biomarkers, 2002Ultra High Field MRS Assessment of MPTP, Rotenone, & BSO Effects in Rodents
Recent technical developments with magnetic resonance spectroscopy (MRS) have provided an extraordinary ability to non-invasively monitor brain function in humans. The neurochemical biopsy afforded...
-
Biomarkers, 2002Non-Invasive Markers of Oxidatvie Stress in Human Brain
Many current theories on the development of Parkinson's disease include the notion that changes in the biochemistry of the brain usually precede any structural changes, which can be picked up by MRI...
-
MJFF Research Grant, 2002Characterization of Alpha Synuclein in Human Fluids & Brain as a Biomarker for Parkinson's Disease
Dr. Michael Schlossmacher and his colleagues at Brigham and Women's Hospital are looking at levels of the protein alpha-synyclein in the blood as a possible biomarker for PD. Mutations in alpha...
-
Fast Track, 2001Lentiviral Delivery of Neublastin to MPTP-Treated Pre-clinical models
Parkinson's disease (PD) results primarily from striatal dopamine (DA) insufficiency and degeneration of dopaminergic neurons within the substantia nigra pars compacta. The cause of PD still remains...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.